弥合治疗差距:识别急性缺血性卒中治疗时间窗内溶栓的当前障碍
该研究为单中心回顾性分析,纳入2020至2022年瑞士卒中登记中4.5小时内到院的急性缺血性卒中患者493例未接受静脉溶栓者。未溶栓主要原因包括症状轻微(41.8%)、既往使用直接口服抗凝药(27%)和神经影像显示分界清楚的亚急性梗死(8.3%)。服用DOAC的患者中50%未检测抗Xa活性。事后影像分析将41.2%最初判读为亚急性梗死的大脑中动脉供血区梗死重新分类为早期脑缺血征象。作者认为识别早期脑缺血征象和获取更多DOAC治疗下溶栓安全性的数据可能改变临床常规并增加适合溶栓的患者数量。
要点
- 4.5小时时间窗内到院的急性缺血性卒中患者中,51.5%(493/958)未接受静脉溶栓。
- 未溶栓的首要原因为症状轻微(41.8%,n=167),其次为既往使用DOAC(27%,n=108)和影像显示分界清楚的亚急性梗死(8.3%,n=41)。
- 服用DOAC的患者中50%(n=54)未检测抗Xa活性。
- 事后影像分析将41.2%(n=14)最初判读为亚急性分界清楚梗死重新分类为早期脑缺血征象。
- 作者认为识别早期脑缺血征象和更多DOAC治疗下溶栓安全性数据可能增加适合溶栓的患者数量。
适用人群与场景
- 2020至2022年在苏黎世大学医院4.5小时治疗时间窗内到院的疑似急性缺血性卒中患者,来自瑞士卒中登记且未接受静脉溶栓者。
研究设计与关键结果
- 研究类型为单中心回顾性分析,纳入瑞士卒中登记中2020至2022年4.5小时内到院的急性缺血性卒中患者493例未接受静脉溶栓者。
- 958例疑似急性缺血性卒中患者在4.5小时内到达苏黎世大学医院,其中493例(51.5%)未接受静脉溶栓。
- 未溶栓主要原因:症状轻微41.8%(n=167),既往使用直接口服抗凝药27%(n=108),神经影像显示分界清楚的亚急性梗死8.3%(n=41)。
- 服用DOAC的患者中,50%(n=54)未检测抗Xa活性。
- 事后影像分析将最初NCCT判读为分界清楚梗死的患者中41.2%(n=14)分类为早期脑缺血征象。
证据类型、等级与局限
- 证据类型:单中心回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为识别早期脑缺血征象和获取更多DOAC治疗下溶栓安全性的数据可能改变临床常规并增加适合静脉溶栓的患者数量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite the proven effectiveness of intravenous thrombolysis (IVT) for patients with acute ischemic stroke (AIS) presenting within 4.5 h of symptom onset, less than 40% receive the treatment. We aimed to understand current reasons for withholding IVT to increase its administration.
METHODS: We conducted a retrospective single-center analysis of AIS patients arriving within the treatment time window of 4.5 h at the hospital not undergoing IVT. 493 patients of the Swiss Stroke Registry (SSR) met the inclusion criteria between 2020 and 2022. We revisited medical records to identify the reasons for not administering IVT.
RESULTS: 958 patients with suspicion of AIS arrived within 4.5 h at the University Hospital Zurich (USZ), 493 (51.5%) did not undergo IVT. The primary reasons for not administering IVT were mild symptoms (41.8%, n = 167), prior use of Direct-Oral-Anticoagulants (DOACs) (27%, n = 108), or a demarcated subacute infarction on neuroimaging (8.3%, n = 41). Among patients with DOAC intake, specific anti-factor-Xa-(aFXa)-activity was not tested in 50% (n = 54). The posthoc-imaging analysis classified 41.2% (n = 14) of patients among the initially described demarcated infarction on NCCT as early signs of brain ischemia (EIS).
CONCLUSION: Mild symptoms and prior DOAC intake were the main reasons for withholding IVT in stroke patients arriving within the treatment time window. Furthermore, EIS on neuroimaging classified as a subacute demarcated infarction by the neuroradiologist in charge constituted another important factor to reconsider IVT among other coexisting reasons. Identification of EIS and more data about the safety of IVT despite DOAC therapy have the potential to change clinical routine and enhance the number of patients suitable for IVT.
参考来源
- Zehnder C, Morra F, Globas C, et al. Closing the treatment gap: Identifying current barriers to thrombolysis in acute ischemic stroke within the treatment time window. Am J Emerg Med. 2026. PMID: 41997008. doi:10.1016/j.ajem.2026.04.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。